

|                          |  |
|--------------------------|--|
| <b>Product Name</b>      | : GSK3145095   |
| <b>Synonyms</b>          | : —  |
| <b>Cat No.</b>           | : M22000   |
| <b>CAS Number</b>        | : 1622849-43-7   |
| <b>Molecular Formula</b> | : C20H17F2N5O2   |
| <b>Formula Weight</b>    | : 397.38   |
| <b>Chemical Name</b>     | : —  |
| <b>Description</b>       | : GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic. GSK3145095 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking RIP1 kinase-dependent cellular responses. Highlighting its potential as a novel cancer therapy, the inhibitor was also able to promote a tumor suppressive T cell phenotype in pancreatic adenocarcinoma organ cultures.? |
| <b>Pathway</b>           | : Apoptosis  |
| <b>Target</b>            | : TNF  |
| <b>Receptor</b>          | : RIP1   |
| <b>Solubility</b>        | : DMSO:245mg/ml (616.54 Mm; Need ultrasonic)   |
| <b>SMILES</b>            | : <chem>FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NNC(CC3=CC=CC=C3)=N2)C(F)=C1</chem>   |
| <b>Storage</b>           | : (-20°C)  |
| <b>Stability</b>         | : ≥ 2 years  |
| <b>Reference</b>         | :  |

1.Harris PA, ET AL. Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862.